Track topics on Twitter Track topics that are important to you
RATIONALE: Cytomegalovirus-specific adoptive cellular therapy and standard antiviral drug therapy may be effective in preventing and treating recurrent cytomegalovirus infections in patients who have undergone stem cell transplant. It is not yet known whether one type of adoptive cellular therapy is more effective than another type in preventing cytomegalovirus infections.
PURPOSE: This randomized phase III trial is comparing standard antiviral drug therapy with two types of adoptive cellular therapy in treating cytomegalovirus infections in patients after donor stem cell transplant.
- To evaluate the potential clinical benefit of immunoprophylactic cytomegalovirus (CMV)-specific adoptive cellular therapy (ACT) and conventional antiviral drug therapy following T-cell-depleted allogeneic hematopoietic stem cell transplantation in terms of reduction in number of recurrent CMV reactivations.
- To evaluate the effect of ACT on graft-versus-host disease (GVHD) incidence.
- To evaluate the effect of ACT on total days of CMV viremia and duration of antiviral drug therapy.
- To evaluate the effect of the selection process (hence cellular composition) of ACT on clinical and immunological endpoints.
- To evaluate the feasibility of centralized production and distribution of an ACT product.
OUTLINE: This is a multicenter study. Patients are stratified according to the availability of multimer selection process. Patients are randomized to 1 of 3* treatment arms. Treatment begins 27 days after allogeneic hematopoietic stem cell transplantation.
NOTE: *Patients for whom multimer selection process is not available are randomize to arm A or arm B.
- Arm A (Standard best available antiviral drug therapy alone): Patients receive standard best available antiviral drug therapy comprising ganciclovir IV twice daily and oral valganciclovir twice daily with or without foscarnet IV twice daily on days 27, 34, 41, 48, 55, 62, 69, 76, 83, 90, 97, 111, 139, 167, and 197.
- Arm B (Adoptive cellular therapy [ACT] and standard best available antiviral drug therapy): Patients receive allogeneic CMV-specific T cells, prepared using Gamma Catch Selection, IV on day 27. They also receive standard best available antiviral drug therapy as in arm A.
- Arm C (ACT and standard best available antiviral drug therapy): Patients receive allogeneic CMV-specific T cells, prepared using Multimer Selection, IV on day 27. They also receive standard best available antiviral drug therapy as in arm A.
After completion of study therapy, patients are followed periodically.
Allocation: Randomized, Control: Active Control, Masking: Open Label, Primary Purpose: Supportive Care
allogeneic cytomegalovirus pp65-specific cytotoxic T lymphocytes, allogeneic cytomegalovirus-specific cytotoxic T lymphocytes, foscarnet sodium, ganciclovir
UCL Cancer Institute
National Cancer Institute (NCI)
Published on BioPortfolio: 2014-08-27T03:13:59-0400
RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus. PURPOSE: This phase I trial is studying how well cytotoxic T c...
CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory ...
This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus [CMV] specific cytotoxic T-lymphocytes [CTLs]) works in ...
The goal of this clinical research study is to learn if giving cytotoxic T lymphocytes (CTLs) can help control CMV when it reactivates (becomes active again) in patients who receive an all...
This study examines the immunologic and virologic effects of prophylactic CMV specific CTL in recipients of T cell depleted stem cell transplant (TCD SCT) at Duke University Medical Cente...
Cytomegalovirus (CMV) infection is a common opportunistic infection after allogeneic haematopoietic stem cell transplantation (HSCT). CMV surveillance-preemptive therapy is the current preferred appro...
Allogeneic hematopoietic stem cell transplantation has proven curative for a range of malignant and nonmalignant disorders. However, the clinical success of this therapy is marred by the morbidity ass...
Cytomegalovirus (CMV)-specific T-cells are crucial to prevent CMV disease. CMV seropositive recipients transplanted with stem cells from a CMV seronegative allogeneic donor (RD) may be at risk for CMV...
Cytomegalovirus (CMV) continues to be one of the most important pathogens that universally affect solid organ and allogeneic hematopoietic stem cell transplant recipients. Lack of effective CMV-specif...
Infection of the retina by cytomegalovirus characterized by retinal necrosis, hemorrhage, vessel sheathing, and retinal edema. Cytomegalovirus retinitis is a major opportunistic infection in AIDS patients and can cause blindness.
An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.
Vaccines or candidate vaccines used to prevent infection with CYTOMEGALOVIRUS.
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...